Treats overactive bladder with symptoms of urge urinary incontinence, urgency and…. ANDA 205209, held by Torrent. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 205209 (Darifenacin Hydrobromide), held by Torrent, was first approved by FDA on Nov 17, 2016, with 1 approved supplement and 0 published complete response letters.
Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 2016 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| May 21, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 17, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters